Please Wait...

Luc Bracoud

Translation skills

Main profile

Luc Bracoud, MSc
Director, Neuroscience

Luc Bracoud graduated from Ecole Centrale Lyon in 2001. He joined Theralys in 2002, which was later acquired by BioClinica (formerly known as Bio-Imaging Technologies) as a software developer and medical image processing engineer. He also served as a project manager, and has been involved in various large multi-center clinical trials mainly in Stroke, MS and AD, as well as Gaucher Disease. His main image processing activities are related to spatial registration, segmentation, atrophy quantification, perfusion imaging, diffusion and diffusion tensor imaging.

Authored Publications

Serge Gauthier, MD, Howard H Feldman, MD, Lon S Schneider, MD, Gordon K Wilcock, DM, Giovanni B Frisoni, MD, Jiri H Hardlund, MD, Hans J Moebius, MD, Peter Bentham, MBChB, Karin A Kook, PhD, Damon J Wischik, PhD, Bjoern O Schelter, Charles S Davis, PhD, Roger T Staff, PhD, Luc Bracoud, MSc, Kohkan Shamsi, MD, John M D Storey, Charles R Harrington, PhD, Claude M Wischik, MBBS.  Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. 15 November 2016. DOI: http://dx.doi.org/10.1016/S0140-6736(16)31275-2.

Coric V, Salloway S, H. van Dyck C, Dubois B, Andreasen N, Brody M, Curtis C, Soininen H, Thein S, Shiovitz T, Pilcher G, Ferris S, Colby S, Kerselaers W, Dockens R, Soares H, Kaplita S, Luo F, Pachai C, Bracoud L, Mintun M, Grill JD, Marek K, Seibyl J, Cedarbaum JM, Albright C, Feldman HH, Berman RM. Targetting Prodromal Alzheimer Disease with Avagacestat A Randomized Clinical Trial.  JAMA Neurol 2015, Sept 28. [Epub ahead of print]

Sibon I, Tourdias T, Felix S, Asselineau J, Bracoud L, Vivot A, Rouanet F, Renou P, Orgogozo JM, Dousset V. Magnetisation transfer parameters and stroke outcome. J Clin Neurosci. 2015 Jun;22(6):1012-7.

Kufner A, Wouters A, Bracoud L, Laage R, Schneider A, Schäbitz W, Hermier M, Thijs V, Fiebach JB, on behalf of the AXIS2 investigators.  Infarct Volume-Based Subgroup Selection in Acute Ischemic Stroke Trials. Stroke, May 2015.

Opherk C, Gonik M, Duering M, Malik R, Jouvent E, Hervé D, Adib-Samii P, Bevan S, Pianese L, Silvestri S, Dotti MT, De Stefano N, Liem M, Boon EM, Pescini F, Pachai C, Bracoud L, Müller-Myhsok B, Meitinger T, Rost N, Pantoni L, Oberstein SL, Federico A, Ragno M, Markus HS, Tournier-Lasserve E, Rosand J, Chabriat H, Dichgans M. Genome-Wide Genotyping Demonstrates a Polygenic Risk Score Associated With White Matter Hyperintensity Volume in CADASIL. Stroke. 2014 Feb 27. [Epub ahead of print]

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

No change order fees for new clients with our #RTSM platform means fewer hurdles as you race to study start. Ready… https://t.co/3mDDIoTbHC
Bioclinica (17 hours ago)
Check out the first post in our CEO David Herron's new blog to find out what makes him a mission-driven leader… https://t.co/HKOdu5Xo0J
Bioclinica (2 weeks ago)
Bioclinica is seeking medical writers with 1-2 years’ experience, imaging research preferred. Great opportunity to… https://t.co/JSFDbQVA6r
Bioclinica (2 weeks ago)
Learn more about how your skills can make a difference at Bioclinica! #Bioclinica #clinicaltrials #clinicalresearch… https://t.co/UAlWZRSCQO
Bioclinica (2 weeks ago)
Read our CEO’s thoughts on Bioclinica’s mission-driven growth agenda. https://t.co/d3OGmHAhK0 #bioclinica… https://t.co/0c2iqAAol6
Bioclinica (2 weeks ago)
Changes are a fact of life - and of #clinicaltrial design. But that doesn't mean planning and budgeting for your tr… https://t.co/BUPFjuIXOt
Bioclinica (3 weeks ago)